Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- US Embassy, ACCJ Seminar Highlights Importance of Prevention
March 24, 2008
- Towa, Nichi-Iko to Hire More New Graduates
March 24, 2008
- Eisai Obtains Option Rights to M's Science's SA4503
March 24, 2008
- Pharmacists Are More Conservative than Doctors about the Use of Generics: CareNet Survey
March 24, 2008
- Sanofi-aventis to Enter Top-10 Club by Doubling Sales: Mr Fauchet
March 24, 2008
- Torrent Withdraws from Japan
March 24, 2008
- REGULATORY NEWS IN BRIEF
March 24, 2008
- Suzuken Renovates Customer Support Services Anticipating Increases in Demand for Generics
March 24, 2008
- Single-Tablet Combination of Galvus and Metformin Approved in EU: Novartis
March 24, 2008
- Nichi-Iko to Become Japan's No. 1 Generic Maker by Acquiring Teikoku Medix
March 24, 2008
- R&D NEWS IN BRIEF
March 24, 2008
- TOPICS 2 articles
March 24, 2008
- BUSINESS NEWS IN BRIEF
March 24, 2008
- Nippon Shinyaku to License NS-304 to Actelion
March 17, 2008
- Molecular-targeted Drugs to Revolutionize the Treatment for Renal Cell Carcinoma: Prof. Akaza
March 17, 2008
- Bendamustine May Become a First-Line Therapy: SymBio
March 17, 2008
- Clexane Added as a New Treatment Option for VTE: sanofi-aventis
March 17, 2008
- Additional Indication for Herceptin to Boost Sales: Chugai
March 17, 2008
- Dr Karasawa Officially Announces His Candidacy
March 17, 2008
- NPhA Announces Policy to Improve Drug Distribution Practices
March 17, 2008
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…